in vitro News and Research

RSS

Protein Erk necessary for nerve fibers to be wrapped with myelin

Researchers at the University of North Carolina at Chapel Hill have pinpointed a crucial function for a key player in the development of the nervous system. They found that this player - a protein called Erk - is necessary for nerve fibers to be wrapped with an insulating substance called myelin, which allows messages to be sent from the brain to the peripheral limbs and back again.

28 Jan 2011

Magnetic nanoparticles for ovarian cancer treatment

A paper published in the January issue of the journal Nanomedicine could provide the foundation for a new ovarian cancer treatment option - one that would use an outside-the-body filtration device to remove a large portion of the free-floating cancer cells that often create secondary tumors.

28 Jan 2011

Positive results from RXi's sd-rxRNA technology for development of novel therapeutics

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, announced today that, as part of its collaboration with miRagen Therapeutics, positive data were generated demonstrating that RXi's sd-rxRNA technology can be used, in vitro, to specifically enhance the activity of a microRNA of high interest to miRagen.

28 Jan 2011

QIAGEN announces formation of subsidiary in India

QIAGEN today announced the formation of its India subsidiary, QIAGEN India Pvt. Ltd., and the beginning of direct sales in the country. Until now, QIAGEN products have been sold in India through distributor partnerships.

From QIAGEN Manchester Limited 27 Jan 2011

Quest Diagnostics releases new data on oral fluid testing system

OraSure Technologies, the market leader in oral fluid diagnostics, announced today that Quest Diagnostics Incorporated released new data indicating that oral fluid revealed approximately five times more heroin use in the general U.S. workforce than previously believed.

From Quest Diagnostics 27 Jan 2011

ECCA and EDMA advance the EU health literacy debate

As part of the 2011 European Cervical Cancer Week, EDMA, the European Diagnostic Manufacturers Association and the ECCA, the European Cervical Cancer Association jointly organised the "Better Health Literacy for Better Health in Europe" dinner debate.

26 Jan 2011

NanoString Technologies launches nCounter Mouse miRNA Expression Assay Kit

NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, today announced the expansion of its microRNA (miRNA) product line with a multiplexed assay for profiling the mouse miRNA transcriptome.

From NanoString Technologies 25 Jan 2011

IRIS International places 40 iQ200 Elite Automated Urine Microscopy Analyzers in Mexico in 2010

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables, and a provider of high value personalized diagnostics testing services through its CLIA certified molecular diagnostics laboratory,has begun to significantly penetrate the Mexican healthcare market with the initial placement in 2010 of 40 iQ®200 Elite™ Automated Urine Microscopy Analyzers within one of the largest social security healthcare systems in Mexico.

25 Jan 2011

Novel FAK inhibitors targeting binding site of VEGFR-3 reduce growth of pancreatic cancer cells

CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, today presented research results at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco demonstrating that novel FAK inhibitors targeting the binding site of vascular endothelial growth factor receptor 3 (VEGFR-3) reduced the growth of pancreatic cancer cells in vitro and in vivo.

21 Jan 2011

Precision highlights role of ChemoFx test, multi-gene predictors for breast cancer

In a new study in which Precision Therapeutics' Multi-Gene Predictors were independently validated by investigators at US Oncology and MD Anderson, Precision highlights the potential role of the ChemoFx® in vitro chemosensitivity test and multi-gene predictors in determining a patient's likelihood of response to multi-drug chemotherapy regimens in breast cancer.

21 Jan 2011

Alliqua completes transdermal pain patch initial study for treatment of PHN

Alliqua, an advanced biomedical products company focused on the development and manufacturing of proprietary drug delivery and liver health technologies, announced today the successful completion of its initial study for the transdermal pain patch project.

20 Jan 2011

Precision Therapeutics to present pancreatic cancer data at 2011 ASCO GI Symposium

Precision Therapeutics, will present pancreatic cancer data based on Precision's ChemoFx in-vitro chemosensitivity test at the 2011 American Society of Clinical Oncology GI Symposium, January 20-22 in San Francisco, California.

20 Jan 2011

4SC initiates dosing in resminostat Phase I/II SHORE study for KRAS-mutant colorectal cancer

4SC AG, a drug discovery and development company, today announced that the first patient has been dosed in the Phase I/II SHORE study with the oral pan-histone deacetylase (HDAC) inhibitor resminostat as a second-line treatment for patients with advanced and metastatic colorectal KRAS-mutant cancer.

20 Jan 2011

Exciton, ULURU sign agreement to develop and market Altrazeal exSALT product

ULURU Inc. announced today that it has signed a Binding Letter of Intent with Exciton Technologies Inc. to develop and market a product that will combine Altrazeal® with Exciton's proprietary exSALT™ Antimicrobial Technology.

20 Jan 2011

Biomarin commences BMN 701 Phase 1/2 trial for treatment of Pompe disease

BioMarin Pharmaceutical Inc. announced today that it has initiated a Phase 1/2 trial for BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase in development for the treatment of Pompe disease.

20 Jan 2011

IntegraMed acquires Northwest Center for Reproductive Sciences

IntegraMed America, Inc., the leader in developing, marketing and managing specialty healthcare facilities in the fertility and vein care markets, announced today that is has acquired Northwest Center for Reproductive Sciences (NCRS).

18 Jan 2011

Better understanding of rotational motion in living cells may help researchers study causes of deadly diseases

Advancements in understanding rotational motion in living cells may help researchers shed light on the causes of deadly diseases, such as Alzheimer's, according to Ning Fang, an associate scientist at the U.S. Department of Energy's Ames Laboratory and faculty member at Iowa State University.

14 Jan 2011